Biohaven Ltd. BHVN
NYSE · United States · Health Technology
$13.14-0.21 (-1.57%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Regeneron Pharmaceuticals (REGN) is back in focus after Biohaven entered a new clinical supply agreement to pair BHV-1530 with Regeneron’s cancer drug Libtayo in patients with solid tumors, with enrollment in the combination cohort already underway. Despite today’s pullback, with the share price down 4.54% over the past day to US$752.25 and weaker recent momentum, Regeneron Pharmaceuticals still carries a 90 day share price return of 20.64% and a 1 year total shareholder return of 34.84%...
Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced that data on BHV-1530, its FGFR3-directed antibody-drug conjugate (ADC) using a novel topoisomerase I (TopoIx) payload, have been accepted for an oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 202
Biohaven has seen its share price fall over several time frames, yet the stock still carries a valuation that ultimately has to rest on what its balance sheet is worth. With the stock changing hands around US$13.19, the live question is how that market value lines up against the company’s book value relative to the broader pharmaceuticals and biotech industry. Over the past 3 years, Biohaven shareholders have seen the stock decline about 49.3%, which puts the focus squarely on whether its...
Xenon Pharmaceuticals says it paused trials for azetukalner in major depressive disorder and bipolar depression following ‘adverse events.’
Warby Parker's 1,500-contract December $22.50 call trade, tied to a stock purchase, signals an institutional covered call. The setup looks bullish on growth and earnings, but a rich valuation, slowing customer growth, and rising capex limit the stock's potential upside.
Pivotal study enrolment has been paused while Biohaven characterises a metabolite of opakalim and its safety in humans.
Biohaven stock plummeted Thursday after the company paused enrollment in a midstage study of its seizure treatment due to safety concerns.
Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.
Announced mere weeks after Biohaven sold off rights to the therapy, opakalim, the halt affects a study some analysts believe is necessary to support a potential approval.
Biohaven Ltd. (NYSE:BHVN) shares fell 17% on Thursday morning after the company paused new patient enrolment in clinical trials of BHV-7000 following a partial clinical hold from the U.
Biohaven said the FDA paused new patient enrollment in the BHV7000-303 trial after nonclinical studies in rodents identified a specific metabolite.
Biohaven (BHVN) is facing a quieter stretch for major drug catalysts, and limited patient data and r
Biohaven Pharmaceutical (NYSE:BHVN) shares fell 1. 9% to $15.
On August 26, Biohaven (NYSE:BHVN) and SK Biopharmaceuticals announced a global licensing agreement covering opakalim, Biohaven’s lead epilepsy candidate, in a deal worth up to $795 million plus royalties. SK Biopharmaceuticals picks up exclusive worldwide rights to Biohaven’s Kv7 ion channel platform, while Biohaven walks away with $400 million in near-term cash. The timing lines […]
By Karen Roman Slate Medicines Inc. said it dosed the first participant in Phase 1 of its clinical study evaluating SLTE-1009, the company’s subcutaneous antibody candidate for migraine treatment. Phase 1 single-and multiple-ascending dose is being conducted in Australia with topline safety data estimated by mid-2027, it stated. READ MORE Final Agenda: 2nd LA CorpGov […] The post Slate Medicines Starts Migraine Treatment Study appeared first on ExecEdge.
SK and Biohaven hope opakalim will show differential benefit to Xenon’s rival focal epilepsy drug, azetukalner, in an upcoming pivotal readout.
Under the agreement, SK Biopharmaceuticals gets exclusive worldwide rights to Biohaven’s Kv7 platform and its lead once-daily pill, opakalim.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.